This PubMed record describes a Correspondence (Letter) titled “Crossing the regulatory and clinical operational valley in antimicrobial resistance: from a start-up's perspective,” published in Lancet Infectious Diseases (2026 Aug;26[8]:e275). The entry provides bibliographic details including DOI 10.1016/S1473-3099(26)00140-4 and PMID 42486124. The record on PubMed does not include an abstract or the substantive body text of the correspondence.
The letter is authored by Venu Gopal Jonnalagadda. The affiliation listed in the PubMed record is Bugworks Research India, Centre for Cellular & Molecular Platforms, National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore 560065, India. The record also lists an electronic contact address for the author. The author’s institutional connection indicates direct involvement with a clinical-stage biopharmaceutical company.
Key identifiers and access points supplied in the PubMed entry:
The PubMed record includes linkouts to full-text sources, including Elsevier Science and ClinicalKey. These links are provided for users who wish to read the full correspondence via the publisher platforms. PubMed itself displays only the citation-level metadata for this item.
A conflict of interest statement is provided in the PubMed record. It states that the author is employed at Bugworks Research India, a clinical-stage biopharmaceutical company developing novel multitarget therapeutic assets in anti-infectives and oncology, and that the author holds stock options in the company through an employee stock ownership plan. The author clarifies that the views expressed in the Correspondence are personal and do not necessarily reflect the official views of the organisation.
The PubMed entry explicitly notes that no abstract is available for this Correspondence. Consequently, the record does not report the letter’s specific content, arguments, data, or recommendations concerning antimicrobial resistance, regulatory hurdles, or clinical operational challenges faced by start-ups. Any detailed description of the letter’s substantive points cannot be reconstructed from the PubMed metadata alone.
Where the title indicates the topic area—regulatory and clinical operational challenges in antimicrobial resistance from a start-up viewpoint—the PubMed source does not supply the letter’s analysis, proposed solutions, case examples, or specific operational details. Therefore, readers must consult the publisher’s full text to access the author’s actual observations and conclusions.
To read the correspondence in full, follow the PubMed-provided linkouts to the publisher platforms (Elsevier Science, ClinicalKey) listed on the citation page. These platforms host the complete content and will show the letter’s text, any referenced evidence, and any author assertions not captured in the PubMed metadata.
When using or citing this letter, note the declared conflict of interest: the author’s employment and stock ownership at Bugworks Research India. Because the PubMed entry includes only citation information and a conflict statement, do not infer specific findings or recommendations from the citation alone. For clinical, regulatory, or operational decision-making related to antimicrobial resistance, rely on the full correspondence text and primary evidence cited therein rather than the PubMed record.
The PubMed entry is useful for locating the correspondence and its bibliographic identifiers but does not substitute for the full text when assessing the author’s positions or evidence.
The letter format (Correspondence) typically signals a brief communication or perspective rather than a full research article; however, the precise length, scope, and evidence cited are not reported in this PubMed record.
Because the author is affiliated with a commercial start-up active in anti-infective development, readers should review the full text alongside the conflict of interest declaration when interpreting the perspectives offered.
In summary, PubMed provides the citation, author affiliation, DOI, PMID, full-text linkouts, and a conflict of interest statement for this correspondence on antimicrobial resistance from a start-up perspective. The substantive content of the letter is not present in the PubMed record; details were not reported in this source and must be obtained from the publisher’s full text.